Can Lilly JAK Olumiant, plagued by side effects, really challenge Dupixent in dermatitis? - FiercePharma

Can Lilly JAK Olumiant, plagued by side effects, really challenge Dupixent in dermatitis?  FiercePharma

Eli Lilly and Incyte's Olumiant has run up against safety hurdles in the past. But can those hurdles stop the drugmakers from adding another feather to the drug's ...



Comments

Post a Comment

Popular posts from this blog

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma - Global Banking And Finance Review

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma    Global Banking And Finance Review Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
Read more